Therapeutic Potential of CKD-504, a Novel Selective Histone Deacetylase 6 Inhibitor, in a Zebrafish Model of Neuromuscular Junction Disorders

• Main Authors: Choi, B.-O (Author), Chung, K.W (Author), Jeong, H.S (Author), Kim, D.-H (Author), Kim, H.J (Author), Lee, J.E (Author)
• Format: Article
• Language: English
• Published: Korean Society for Molecular and Cellular Biology 2022
• Subjects: CKD-504; GARS; HDAC6 inhibitor; neuromuscular junction; zebrafish
• Online Access: View Fulltext in Publisher

 The neuromuscular junction (NMJ), which is a synapse for signal transmission from motor neurons to muscle cells, has emerged as an important region because of its association with several peripheral neuropathies. In particular, mutations in GARS that affect the formation of NMJ result in Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. These disorders are mainly considered to be caused by neuronal axon abnormalities; however, no treatment is currently available. Therefore, in order to determine whether the NMJ could be targeted to treat neurodegenerative disorders, we investigated the NMJ recovery effect of HDAC6 inhibitors, which have been used in the treatment of several peripheral neuropathies. In the present study, we demonstrated that HDAC6 inhibition was sufficient to enhance movement by restoring NMJ impairments observed in a zebrafish disease model. We found that CKD-504, a novel HDAC6 inhibitor, was effective in repairing NMJ defects, suggesting that treatment of neurodegenerative diseases via NMJ targeting is possible. © The Korean Society for Molecular and Cellular Biology.